Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer

Li, Wenjing; Wang, Zheng; Gao, Tian; Sun, Shengkai; Xu, Mingsheng; Pei, Renjun

doi:10.1039/d1tb02729h

Cited by 6 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, a chimeric drug that is a CD133-targeted DNA aptamer combined with doxorubicin showed selective killing effect in human colorectal cancer HCT116 cells expressing CD133. The in vitro and in vivo results demonstrated the high therapeutic efficacy and low toxicity of this chimera [112]. Also, recent in vitro study has shown the effective use of Fc-optimized antibodies against CD133 to induce natural killer (NK) cell reactivity [113].…”

Section: Cd133 As a Target Of Therapies Aimed To Eliminate The Most M...mentioning

confidence: 90%

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Gisina,

Kim,

Yarygin

et al. 2023

IJMS

View full text Add to dashboard Cite

The CD133 cell membrane glycoprotein, also termed prominin-1, is expressed on some of the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were shown to exhibit higher proliferative activity, greater chemo- and radioresistance, and enhanced tumorigenicity compared to their CD133-negative counterparts. For this reason, CD133 is regarded as a potential prognostic biomarker in oncology. The CD133-positive cells are related to the cancer stem cell subpopulation in many types of cancer. Recent studies demonstrated the involvement of CD133 in the regulation of proliferation, autophagy, and apoptosis in cancer cells. There is also evidence of its participation in the epithelial–mesenchymal transition associated with tumor progression. For a number of malignant tumor types, high CD133 expression is associated with poor prognosis, and the prognostic significance of CD133 has been confirmed in a number of meta-analyses. However, some published papers suggest that CD133 has no prognostic significance or even demonstrate a certain correlation between high CD133 levels and a positive prognosis. This review summarizes and discusses the existing evidence for and against the prognostic significance of CD133 in cancer. We also consider possible reasons for conflicting findings from the studies of the clinical significance of CD133.

show abstract

Section: Cd133 As a Target Of Therapies Aimed To Eliminate The Most M...mentioning

confidence: 90%

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Gisina,

Kim,

Yarygin

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…They are not only able to penetrate into the solid tumor better than antibodies but are also internalized in the cell by receptor-mediated endocytosis [ 138 ]. Aptamers can be used as a component in sensor detection systems [ 139 ] and in vectors for drug delivery to cancer stem cells [ 140 , 141 , 142 , 143 , 144 ]. In addition to aptamers, peptides capable of specific binding to CD133 can be selected using phage display peptide libraries and the systematic evolution of ligands by exponential enrichment [ 145 ].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

Gisina,

Yarygin,

Lupatov

2024

Biology

View full text Add to dashboard Cite

The membrane glycoprotein CD133 (prominin-1) is widely regarded as the main molecular marker of cancer stem cells, which are the most malignant cell subpopulation within the tumor, responsible for tumor growth and metastasis. For this reason, CD133 is considered a promising prognostic biomarker and molecular target for antitumor therapy. Under normal conditions, CD133 is present on the cell membrane in glycosylated form. However, in malignancies, altered glycosylation apparently leads to changes in the functional activity of CD133 and the availability of some of its epitopes for antibodies. This review focuses on CD133’s glycosylation in human cells and its impact on the function of this glycoprotein. The association of CD133 with proliferation, differentiation, apoptosis, autophagy, epithelial–mesenchymal transition, the organization of plasma membrane protrusions and extracellular trafficking is discussed. In this review, particular attention is paid to the influence of CD133’s glycosylation on its immunodetection. A list of commercially available and custom antibodies with their characteristics is provided. The available data indicate that the development of CD133-based biomedical technologies should include an assessment of CD133’s glycosylation in each tumor type.

show abstract

Screening and specificity study of aptamer of common proteins in colorectal cancer

Sun

Shi

Liu

et al. 2022

Chinese Journal of Analytical Chemistry

View full text Add to dashboard Cite

Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer

Abstract: Tumor-targeted delivery of antitumor drugs is considered a promising strategy for improving chemotherapeutic efficiency and reducing the incidence of side effects. The development of tumor-targeted aptamers to accommodate drugs has...

Cited by 6 publications

References 32 publications

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

Screening and specificity study of aptamer of common proteins in colorectal cancer

Contact Info

Product

Resources

About